Company intelligence / Profile preview

Qinghai Spring Medicinal Resources Technology

Xining, Qinghai Province, China

Ownership: Private
Employees: ~173
Development stage: Commercial

Overview

Qinghai Spring has commercialized several cordyceps-based traditional Chinese medicines and health supplements. Its core product line includes pure ophiocordyceps sinensis powder and compound decoctions based on classical TCM prescriptions. No clinical trial data per international standards reported; products are sold as TCM or consumer health goods.

Therapeutic areas: OtherNephrologyHematology
Modalities: Traditional Chinese medicine productHerbal medicine/extracts
Industry: Food & Nutrition

Drug pipeline

1 asset

cordyceps sinensis

Commercial

Beyond the preview

Go deeper on Qinghai Spring Medicinal Resources Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qinghai Spring Medicinal Resources Technology.

Explore the full profile